Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Eledon Pharmaceuticals Inc
Healthcare
P/NCAV
1.05x
Ticker
ELDN
Exchange
NASDAQ
Country
United States
Close
2.16 $
Mkt Cap
53.2M $
EV
48.6M $
NCAV Burn Rate
0.8%
Current Ratio
14.41
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
-1.1x
EV/FCF
-1.2x
Dilution
77.8% p.A
Total Net Income
-335.1M $
Cheapness
73.0%
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average